Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.
Smits F, Groen K, Levin MD, Stege C, van Kampen RJW, van der Spek E, Bilgin YM, Thielen N, Nijhof IS, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, Heer K, Vekemans MM, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S. Smits F, et al. Among authors: van de donk nwcj. Blood. 2024 Nov 22:blood.2024025868. doi: 10.1182/blood.2024025868. Online ahead of print. Blood. 2024. PMID: 39576961
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC. van de Donk NW, et al. Cancer Manag Res. 2012;4:253-68. doi: 10.2147/CMAR.S27087. Epub 2012 Aug 14. Cancer Manag Res. 2012. PMID: 22956884 Free PMC article.
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens AC, Mutis T. Nijhof IS, et al. Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398450
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S, van der Holt B, Mellqvist UH, Salomo M, Bos GM, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden AW, Deenik W, Gruber A, Coenen JL, Plesner T, Klein SK, Tanis BC, Szatkowski DL, Brouwer RE, Westerman M, Leys MR, Sinnige HA, Haukås E, van der Hem KG, Durian MF, Mattijssen EV, van de Donk NW, Stevens-Kroef MJ, Sonneveld P, Waage A. Zweegman S, et al. Blood. 2016 Mar 3;127(9):1109-16. doi: 10.1182/blood-2015-11-679415. Epub 2016 Jan 22. Blood. 2016. PMID: 26802176 Free article. Clinical Trial.
225 results